Citi Downgrades Moonlake Immunotherapeutics (MLTX) to Sell
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Price: $15.06 -0.46%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
Citi analyst Samantha Semenkow downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Neutral to Sell with a price target of $5.00.
For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.
Shares of Moonlake Immunotherapeutics closed at $9.82 yesterday.
You May Also Be Interested In
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Guggenheim Downgrades Alumis Inc (ALMS) to Neutral
- Morgan Stanley Downgrades Barclays Plc (BARC:LN) (BCS) to Equalweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
